MarketCapExport financials
Vertex Pharmaceuticals Incorporated (VRTX)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Vertex Pharmaceuticals Incorporated Cash Flow 2025-2007 | VRTX
Brief overview of Vertex Pharmaceuticals Incorporated's cash generation
The comparison covers five available annual reports between 2021 and 2025.
Operating cash flow increased from $2.6 billion to $3.6 billion, gaining +37.4%. CAGR near 8.3% reflects steady momentum.
Operating cash flow was positive in 4 of five periods. Cash generation worked overall but was not fully stable.
The cash conversion ratio reached 1.06x. Cash generation matched or exceeded accounting profit.
Operating cash flow margin dropped from 34.9% to 30.3%. Sales produced less cash per unit.
Working capital needs increased $2 billion, or 16.5% of sales. This may restrain cash conversion.
Cash flow takeaway
Vertex Pharmaceuticals Incorporated's cash flows are broadly resilient, though selected ratios need monitoring. Positive earnings conversion and moderate investment demand remain important.
Annual Cash Flow Vertex Pharmaceuticals Incorporated
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow |
3.63 B | -493 M | 3.54 B | 4.13 B | 2.64 B | 3.25 B | 1.57 B | 1.27 B | 845 M | 236 M | -365 M | -573 M | -60.7 M | 268 M | 144 M | -635 M | -428 M | -226 M | - |
Depreciation & Amortization |
210 M | 207 M | 181 M | 148 M | 126 M | 110 M | 107 M | 72.4 M | 61.4 M | 61.4 M | 62.3 M | 63.3 M | 48.4 M | 38.2 M | 35 M | 30.5 M | 30.1 M | 32.2 M | - |
Accounts Payables |
462 M | 413 M | 365 M | 304 M | 195 M | 155 M | 87.6 M | 111 M | 74 M | 61.5 M | 74.9 M | 71.2 M | 49.3 M | 101 M | 74.6 M | 35.9 M | 37 M | - | - |
Accounts Receivables |
2.05 B | 1.61 B | 1.56 B | 1.44 B | 1.14 B | 885 M | 634 M | 410 M | 281 M | 201 M | 178 M | 76 M | 85.5 M | 143 M | 183 M | 12.5 M | 9.6 M | - | - |
Total Inventories |
1.69 B | 1.21 B | 739 M | 461 M | 353 M | 281 M | 168 M | 124 M | 112 M | 77.6 M | 57.2 M | 30.8 M | 14.1 M | 30.5 M | 112 M | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Cash Flow Vertex Pharmaceuticals Incorporated
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | 2010-Q3 | 2010-Q2 | 2010-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow |
2.55 B | 1.43 B | - | - | - | 819 M | - | - | - | 1.31 B | - | - | - | 900 M | - | 3.05 B | - | 956 M | - | 1.65 B | - | 921 M | - | 2.76 B | 1.85 B | 816 M | - | 1.12 B | 789 M | 325 M | - | 956 M | 574 M | 253 M | - | 617 M | 447 M | 266 M | - | 91.4 M | 25.7 M | -15.1 M | - | -395 M | -333 M | -222 M | - | -391 M | -304 M | -176 M | - | -80.4 M | -66.7 M | -65.8 M | - | 227 M | 121 M | 2.92 M | - | - | - | -187 M | -469 M | -305 M | -196 M |
Depreciation & Amortization |
56.5 M | 55.9 M | - | 54 M | 51.7 M | 48.4 M | - | 53.2 M | 54 M | 53.5 M | - | - | - | 38.8 M | - | 110 M | - | 35.9 M | - | 91.8 M | - | 28.8 M | - | 80.2 M | 53.5 M | 26.8 M | - | 80.7 M | 54.8 M | 27.1 M | - | 53.6 M | 34.4 M | 16.3 M | - | 45 M | 29.7 M | 14.8 M | - | 45.9 M | 31.4 M | 16.4 M | - | 46.6 M | 30.4 M | 16.4 M | - | 46.9 M | 30 M | 15.8 M | - | 30.7 M | 21.2 M | 10.7 M | - | 25.8 M | 17.2 M | 8.56 M | - | 25.3 M | 17.6 M | 8.86 M | 22.3 M | 15.5 M | 7.58 M |
Accounts Payables |
430 M | 489 M | 462 M | 420 M | 442 M | 445 M | 413 M | 396 M | 328 M | 351 M | 365 M | 376 M | 363 M | 323 M | 304 M | 127 M | - | 174 M | 195 M | 128 M | 128 M | 128 M | 155 M | 155 M | 155 M | 155 M | 87.6 M | 87.6 M | 87.6 M | 87.6 M | 111 M | 111 M | 111 M | 111 M | 74 M | 74 M | 74 M | 74 M | 61.5 M | 61.5 M | 61.5 M | 61.5 M | 74.9 M | 74.9 M | 74.9 M | 74.9 M | 71.2 M | 71.2 M | 71.2 M | 71.2 M | 49.3 M | 49.3 M | 49.3 M | 49.3 M | 101 M | 101 M | 101 M | 101 M | 74.6 M | 74.6 M | 74.6 M | 74.6 M | 24.6 M | 46.5 M | 29.1 M |
Accounts Receivables |
2.13 B | 2 B | 2.05 B | 1.95 B | 1.89 B | 1.81 B | 1.61 B | 1.75 B | 1.66 B | 1.79 B | 1.56 B | 1.54 B | 1.56 B | 1.55 B | 1.44 B | 1.39 B | - | 1.29 B | 1.14 B | 1.1 B | 929 M | 978 M | 885 M | 885 M | 885 M | 885 M | 634 M | 634 M | 634 M | 634 M | 410 M | 410 M | 410 M | 410 M | 281 M | 281 M | 281 M | 281 M | 200 M | 201 M | 201 M | 201 M | 174 M | 174 M | 178 M | 178 M | 76 M | 76 M | 76 M | 76 M | 85.5 M | 85.5 M | 85.5 M | 85.5 M | 143 M | 143 M | 143 M | 143 M | 183 M | 183 M | 183 M | 183 M | 4.96 M | 3.55 M | 7.88 M |
Total Inventories |
1.77 B | 1.77 B | 1.69 B | 1.63 B | 1.5 B | 1.36 B | 1.21 B | 1.08 B | 915 M | 813 M | 739 M | 689 M | 604 M | 535 M | 461 M | 388 M | - | 339 M | 353 M | 333 M | 322 M | 299 M | 281 M | 281 M | 281 M | 281 M | 168 M | 168 M | 168 M | 168 M | 124 M | 124 M | 124 M | 124 M | 112 M | 112 M | 112 M | 112 M | 77.6 M | 77.6 M | 77.6 M | 77.6 M | 57.2 M | 57.2 M | 57.2 M | 57.2 M | 30.8 M | 30.8 M | 30.8 M | 30.8 M | 14.1 M | 14.1 M | 14.1 M | 14.1 M | 30.5 M | 30.5 M | 30.5 M | 30.5 M | 112 M | 112 M | 112 M | 112 M | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Cash Flow Statement is one of the three key financial reports of the company Vertex Pharmaceuticals Incorporated, reflecting the actual cash inflows and outflows over a certain period. Unlike the income statement, which shows revenues and expenses on an accrual basis, the cash flow statement focuses on real cash flows — how much cash actually came into the company and how much was spent.
Main Sections of the Cash Flow Statement- Operating Activities
This section reflects cash flows related to the company’s core operations: receipts from sales of goods and services, payments to suppliers, employee salaries, taxes, and other operating expenses. Positive cash flow from operating activities indicates the viability of the business and its ability to generate cash. - Investing Activities
Shows cash movements related to the purchase and sale of long-term assets such as real estate, equipment, and investments in other companies. Negative cash flow here often indicates investments in growth, which can be a positive sign. - Financing Activities
Reflects the inflow and outflow of cash related to raising and repaying capital: issuing shares, loans, dividend payments, and loan repayments. This section shows how the company finances its activities and distributes profits.
The cash flow statement is important for investors because it allows them to assess the company’s real liquidity, showing whether it has enough cash to cover current obligations and investments — this is critical for financial stability. Additionally, it helps analyze the quality of earnings, since profits reported in the income statement can be "paper" profits and may not reflect actual cash inflows; the cash flow statement reveals this difference. The presence of free cash is also crucial for evaluating the company’s ability to finance growth and pay dividends, which is important for investors. Attention should also be paid to prolonged negative cash flows from operating activities, as this may serve as a warning sign of potential problems with the core business.
Cash flow statements of other stocks in the Biotechnology sector
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
vTv Therapeutics
VTVT
|
$ 26.54 | 0.25 % | $ 105 M |  USA |
 |
Voyager Therapeutics
VYGR
|
$ 1.9 | 2.49 % | $ 112 M | USA |
 |
Genprex
GNPX
|
$ 2.11 | 1.31 % | $ 1.97 M | USA |
 |
Wave Life Sciences Ltd.
WVE
|
$ 3.13 | 0.78 % | $ 528 M |  Singapore |
 |
Agenus
AGEN
|
$ 6.04 | 2.77 % | $ 180 M | USA |
 |
Xenetic Biosciences
XBIO
|
$ 1.98 | 0.48 % | $ 3.37 M | USA |
 |
Keros Therapeutics
KROS
|
$ 10.66 | 0.45 % | $ 397 M | USA |
 |
XBiotech
XBIT
|
$ 2.12 | 1.67 % | $ 64.6 M | USA |
 |
Xenon Pharmaceuticals
XENE
|
$ 33.49 | 1.27 % | $ 2.65 B |  Canada |
 |
Xeris Pharmaceuticals
XERS
|
$ 10.31 | 2.38 % | $ 1.65 B | USA |
 |
X4 Pharmaceuticals
XFOR
|
$ 2.59 | 0.19 % | $ 110 M | USA |
 |
Kodiak Sciences
KOD
|
$ 85.75 | 0.64 % | $ 4.56 B | USA |
 |
22nd Century Group
XXII
|
$ 0.34 | 0.98 % | $ 62.6 K | USA |
 |
Halozyme Therapeutics
HALO
|
$ 121.84 | 0.27 % | $ 14.6 B | USA |
 |
Arvinas
ARVN
|
$ 6.97 | 1.12 % | $ 494 M | USA |
 |
Zai Lab Limited
ZLAB
|
$ 23.19 | 0.79 % | $ 25.4 B |  China |
 |
Zentalis Pharmaceuticals
ZNTL
|
$ 2.13 | 0.83 % | $ 153 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
$ 1.6 | 1.78 % | $ 426 M |  Britain |
 |
BridgeBio Pharma
BBIO
|
$ 66.39 | 3.37 % | $ 12.7 B | USA |
 |
PMV Pharmaceuticals
PMVP
|
$ 1.21 | 4.03 % | $ 63.6 M | USA |
 |
Harmony Biosciences Holdings
HRMY
|
$ 37.95 | 0.17 % | $ 2.18 B | USA |
 |
Kazia Therapeutics Limited
KZIA
|
$ 7.25 | 0.54 % | $ 111 M |  Australia |
 |
CNS Pharmaceuticals
CNSP
|
$ 4.85 | 3.08 % | $ 2.15 M | USA |
 |
MacroGenics
MGNX
|
$ 3.25 | 1.81 % | $ 205 M | USA |
 |
iBio
IBIO
|
$ 0.77 | 0.63 % | $ 80.1 M | USA |
 |
Cytokinetics, Incorporated
CYTK
|
$ 61.95 | 0.77 % | $ 7.44 M | USA |
 |
Immunome
IMNM
|
$ 16.47 | 1.16 % | $ 1.44 B | USA |
 |
Immuron Limited
IMRN
|
$ 0.98 | 0.49 % | $ 226 M | Australia |
 |
Moderna
MRNA
|
$ 218.01 | 4.51 % | $ 84.8 B | USA |
 |
InMed Pharmaceuticals
INM
|
$ 1.32 | 0.38 % | $ 5.5 M | Canada |
 |
INmune Bio
INMB
|
$ 1.57 | 3.12 % | $ 38.9 M | USA |
 |
Inovio Pharmaceuticals
INO
|
$ 0.99 | 5.48 % | $ 46.4 M | USA |
 |
Insmed Incorporated
INSM
|
$ 96.27 | 1.45 % | $ 19.2 B | USA |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
$ 10.78 | 4.62 % | $ 697 M | USA |
 |
Biogen
BIIB
|
$ 232.65 | 0.1 % | $ 34.1 B | USA |
 |
BioVie
BIVI
|
$ 1.2 | 6.19 % | $ 1.77 M | USA |
 |
Ionis Pharmaceuticals
IONS
|
$ 42.94 | 3.33 % | $ 6.87 B | USA |
 |
Innate Pharma S.A.
IPHA
|
$ 1.43 | 0.54 % | $ 128 M |  France |
 |
NextCure
NXTC
|
$ 6.24 | 4.56 % | $ 17.7 M | USA |
 |
BeyondSpring
BYSI
|
$ 0.56 | 3.09 % | $ 23 M | USA |
 |
Capricor Therapeutics
CAPR
|
$ 6.71 | 10.32 % | $ 312 M | USA |
 |
Oncolytics Biotech
ONCY
|
$ 0.5 | 1.75 % | $ 47.9 M | Canada |
 |
Outlook Therapeutics
OTLK
|
$ 0.49 | 0.04 % | $ 17.1 M | USA |
 |
Protagonist Therapeutics
PTGX
|
$ 128.75 | 0.2 % | $ 8.19 B | USA |
 |
Passage Bio
PASG
|
$ 3.5 | 4.44 % | $ 11.2 M | USA |
|
Forte Biosciences
FBRX
|
$ 76.99 | 0.03 % | $ 997 M | USA |
 |
Mirum Pharmaceuticals
MIRM
|
$ 80.14 | 3.04 % | $ 4.02 B | USA |
 |
Inhibikase Therapeutics
IKT
|
$ 1.65 | 1.67 % | $ 162 M | USA |
|
Immatics N.V.
IMTX
|
$ 6.73 | 2.0 % | $ 823 M |  Germany |